Dengue in Thailand and Cambodia: An Assessment of the Degree of Underrecognized Disease Burden Based on Reported Cases

BACKGROUND Disease incidence data are needed to guide decision-making for public health interventions. Although dengue is a reportable disease in Thailand and Cambodia, the degree that reported incidence underrecognizes true disease burden is unknown. We utilized dengue incidence calculated from laboratory-confirmed outpatient and inpatient cases in prospective cohort studies to estimate the magnitude of dengue underrecognition and to establish more accurate disease burden estimates for these countries. METHODS AND FINDINGS Cohort studies were conducted among children aged <15 years by members of a dengue field site consortium over at least 2 dengue seasons. Age-group specific multiplication factors (MFs) were computed by comparing data from three cohort studies to national surveillance data in the same province and year. In Thailand, 14,627 person-years of prospective cohort data were obtained in two provinces and 14,493 person-years from one province in Cambodia. Average annual incidence of laboratory-confirmed dengue was 23/1,000 and 25/1,000 in Thailand, and 41/1,000 in Cambodia. Calculated MFs in these provinces varied by age-group and year (range 0.4-29). Average age-group specific MFs were then applied to country-level reporting data and indicated that in Thailand a median 229,886 (range 210,612-331,236) dengue cases occurred annually during 2003-2007 and a median 111,178 (range 80,452-357,135) cases occurred in Cambodia in children <15 years of age. Average underrecognition of total and inpatient dengue cases was 8.7 and 2.6-fold in Thailand, and 9.1 and 1.4-fold in Cambodia, respectively. During the high-incidence year 2007, >95,000 children in Thailand and >58,000 children in Cambodia were estimated to be hospitalized due to dengue. CONCLUSION Calculating MFs by comparing prospective cohort study data to locally-reported national surveillance data is one approach to more accurately assess disease burden. These data indicate that although dengue is regularly reported in many countries, national surveillance data significantly underrecognize the true burden of disease.

[1]  R. Lanciotti,et al.  Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction , 1992, Journal of clinical microbiology.

[2]  Jacqueline L Deen,et al.  The WHO dengue classification and case definitions: time for a reassessment , 2006, The Lancet.

[3]  Michael Marx,et al.  What does dengue disease surveillance contribute to predicting and detecting outbreaks and describing trends? , 2008, Tropical medicine & international health : TM & IH.

[4]  Stefan Hoyer,et al.  Improved Molecular Detection of Dengue Virus Serotype 1 Variants , 2003, Journal of Clinical Microbiology.

[5]  Aree Kantachuvessiri,et al.  Dengue hemorrhagic fever in Thai society. , 2002, The Southeast Asian journal of tropical medicine and public health.

[6]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.

[7]  M. Aye,et al.  Risk factors in dengue shock syndrome. , 1997, The American journal of tropical medicine and hygiene.

[8]  Alan L Rothman,et al.  Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages , 2008, PLoS medicine.

[9]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[10]  Majid Ezzati,et al.  Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework , 2007, PLoS neglected tropical diseases.

[11]  Colin Mathers,et al.  The Global epidemiology of infectious diseases , 2004 .

[12]  P. Glaziou,et al.  Secondary dengue virus type 4 infections in Vietnam. , 2005, The Southeast Asian journal of tropical medicine and public health.

[13]  M. Guzmán,et al.  Dengue: an update. , 2002, The Lancet. Infectious diseases.

[14]  A. Nisalak,et al.  Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study , 2007, The Lancet.

[15]  A. Nisalak,et al.  Hemorrhagic fever in Cambodia is caused by dengue viruses: evidence for transmission of all four serotypes. , 1997, The Southeast Asian journal of tropical medicine and public health.

[16]  S. Halstead,et al.  A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. , 1999, The American journal of tropical medicine and hygiene.

[17]  B. Guy,et al.  Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. , 2008, Vaccine.

[18]  Wilbur G Downs,et al.  Dengue Hemorrhagic Fever: Diagnosis, Treatment and Control: by the World Health Organization vii + 58 pages, illustrated, World Health Organization, 1211 Geneva 27, Switzerland. 1986. $7.80 , 1987 .

[19]  D. Gubler,et al.  Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. , 1998, The American journal of tropical medicine and hygiene.

[20]  Philippe Buchy,et al.  Dengue Incidence in Urban and Rural Cambodia: Results from Population-Based Active Fever Surveillance, 2006–2008 , 2010, PLoS neglected tropical diseases.

[21]  D. Shepard,et al.  Cost‐effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti , 2007, Tropical medicine & international health : TM & IH.

[22]  A. Galvani,et al.  Disability adjusted life years lost to dengue in Brazil , 2009, Tropical medicine & international health : TM & IH.

[23]  Dengue severity throughout seasonal changes in incidence in Puerto Rico, 1989-1992. The Puerto Rico Association of Epidemiologists. , 1994, The American journal of tropical medicine and hygiene.

[24]  D. Vaughn,et al.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults , 2009, Human vaccines.